Sonic Healthcare Agrees US$150 Million Acquisition of Pathology Watch
By Stuart Condie
SYDNEY--Sonic Healthcare acquired Utah-based medical-tech provider Pathology Watch for US$150 million in what the Australian company called a strategic move that would accelerate its transition to digital pathology services.
Sonic on Thursday said that it would fund the acquisition from existing cash reserves and debt. Pathology Watch is currently at the pre-profit stage, but Sonic expects attractive earnings-per-share and return-on-invested-capital accretion over coming years.
Sonic added that Pathology Watch's founders, management and staff of Pathology Watch will join the ASX-listed company's U.S. and global operations. The deal is expected to close in December 2023.
"The acquisition of Pathology Watch is an important and enormously exciting step in Sonic's transition to digital pathology and pathology AI and offers multiple avenues for value creation," Sonic Chief Executive Colin Goldschmidt said.
The transaction is not material, Sonic said.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
November 15, 2023 17:42 ET (22:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending